COMPANY
Sumitomo Pharma America, Inc.
FDA-approved therapeutic company Clinical Phase 3
Hiring
| Title | Location (from posting) | Employer posted | First seen |
|---|---|---|---|
| Corporate Communications Manager | US-Remote | Oct 21, 2026 | Oct 22, 2026 |
| Medical Science Liaison / Senior Medical Science Liaison – Specialty (Great Plains) | US-Remote | Oct 20, 2026 | Oct 21, 2026 |
| Medical Science Liaison – Sr. Medical Science Liaison Specialty (Midwest) | US-IL-Chicago | Oct 19, 2026 | Oct 20, 2026 |
| Medical Science Liaison - Sr. Medical Science Liaison (Ohio Valley)-Oncology | 2 locations (listed on the posting) | Oct 19, 2026 | Oct 20, 2026 |
| Medical Science Liaison – Sr. Medical Science Liaison Specialty (Ohio Valley) | 3 locations (listed on the posting) | Oct 19, 2026 | Oct 20, 2026 |
Timeline
- Board tracked Radar started tracking this company’s job board (36 open jobs at last check). source ↗
- Trial start Phase 1/Phase 2: A Study to Investigate the Safety of DSP-3077 After a Unilateral Eye Injection in Male and Female Participants 18 Years of Age or Older With Retinitis Pigmentosa source ↗
- Trial start Phase 1: How [14C]-DSP-5336 is Absorbed, Broken Down, and Removed From the Body After a Single Oral Dose in Patients With Advanced Blood Cancers source ↗
- Trial start Phase 1/Phase 2: A Multicenter Study to Evaluate Safety, Tolerability, and Clinical Responses of DSP-1083 Into Subjects With Parkinson's Disease source ↗
- FDA FDA New indication / efficacy supplement: ORGOVYX (relugolix) — NDA214621/6, Oct 18, 2024. Applicant at approval: Sumitomo Pharma America, Inc. source ↗
- Trial start —: A Prospective, Observational Study in Adults With Retinitis Pigmentosa (RP) source ↗
- Trial start Phase 1/Phase 2: SMP-3124LP in Adults With Advanced Solid Tumors source ↗
- Trial start Phase 1: TP-3654 Food Effect Study source ↗
- Trial start Not phased (device or behavioral study): A Randomized, Controlled Study of Two At-Home Self-Guided Virtual Reality Interventions for Adults With Social Anxiety Disorder. source ↗
- Trial start Phase 1: Assessment of Relative Bioavailability and Effect of Food on Capsule and Tablet Formulations of TP-3654 source ↗
- Trial start Phase 3: Randomized Study to Evaluate MACE in Patients With Prostate Cancer Treated With Relugolix or Leuprolide Acetate source ↗
- Trial start —: A Multi-Center, Prospective, Observational Study of Patients Being Treated With ORGOVYX source ↗
- Trial start Phase 3: A Clinical Trial to Determine the Long-term Safety and Tolerability of an Investigational Drug in People With Major Depressive Episode Associated With Bipolar I Disorder (Bipolar I Depression source ↗
- Trial start 1: A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1) source ↗
- Trial start Phase 3: A Clinical Study of an Investigational Drug for the Treatment of Major Depressive Episode Associated With Bipolar I Disorder. source ↗
- Trial start Early phase 1: Study of DSP-0390 in Patients With Recurrent High-Grade Glioma source ↗
- Trial start Phase 1: Study of Relugolix in Men With Metastatic Castration-Sensitive Prostate Cancer or Non-Metastatic or Metastatic Castration-Resistant Prostate Cancer source ↗
- Trial start 1: Phase 1 Study of Oral TP-1454 source ↗
- Trial start Phase 2: Study of Alvocidib in Patients With Relapsed/Refractory AML Following Treatment With Venetoclax Combination Therapy source ↗
- Trial start Phase 1/Phase 2: A Study of Oral Nuvisertib (TP-3654) in Patients With Myelofibrosis source ↗
- Trial start Phase 1: Study of TP-3654 in Patients With Advanced Solid Tumors source ↗
- Trial start 1: Phase 1, First-in-human Study of Oral TP-1287 in Patients with Advanced Solid Tumors source ↗
- Trial start Phase 1: First-in-human Study of Oral TP-0184 in Patients With Advanced Solid Tumors source ↗
- Trial start Phase 1/Phase 2: A Study of DSP-0509 in Patients With Advanced Solid Tumors to Determine the Safety and the Pharmacokinetic Profile source ↗
- Trial start Phase 1: A Study of DSP-0337 in Patients With Advanced Solid Tumors to Determine the Safety and the Pharmacokinetic Profile source ↗
Upcoming milestones
- Apr 30, 2027 (ESTIMATED) · Phase 1/Phase 2 · A Study of Oral Nuvisertib (TP-3654) in Patients With Myelofibrosis · NCT04176198
- Jun 30, 2027 (ESTIMATED) · 1 · A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1) · NCT04988555
- Sep 30, 2027 (ESTIMATED) · Early phase 1 · Study of DSP-0390 in Patients With Recurrent High-Grade Glioma · NCT05023551
- Oct 31, 2028 (ESTIMATED) · Phase 1/Phase 2 · A Study to Investigate the Safety of DSP-3077 After a Unilateral Eye Injection in Male and Female Participants 18 Years of Age or Older With Retinitis Pigmentosa · NCT06891885
- 2028-12 (ESTIMATED) · Phase 1/Phase 2 · SMP-3124LP in Adults With Advanced Solid Tumors · NCT06526819
- Dec 15, 2030 (ESTIMATED) · Phase 1/Phase 2 · A Multicenter Study to Evaluate Safety, Tolerability, and Clinical Responses of DSP-1083 Into Subjects With Parkinson's Disease · NCT06753331
Open jobs 36
Clinical trials (lead sponsor) Showing 50 of 181
| Record | Title | Phase | Status | Start | Primary completion |
|---|---|---|---|---|---|
| NCT06526819 | SMP-3124LP in Adults With Advanced Solid Tumors | Phase 1/Phase 2 | Recruiting | Aug 14, 2024 | 2028-12 (estimated) |
| NCT04176198 | A Study of Oral Nuvisertib (TP-3654) in Patients With Myelofibrosis | Phase 1/Phase 2 | Recruiting | Dec 16, 2019 | Apr 30, 2027 (estimated) |
| NCT07444268 | How [14C]-DSP-5336 is Absorbed, Broken Down, and Removed From the Body After a Single Oral Dose in Patients With Advanced Blood Cancers | Phase 1 | Completed | Mar 26, 2026 | Aug 11, 2026 (actual) |
| NCT05023551 | Study of DSP-0390 in Patients With Recurrent High-Grade Glioma | Early phase 1 | Active, not recruiting | Sep 8, 2021 | Sep 30, 2027 (estimated) |
| NCT05467176 | A Multi-Center, Prospective, Observational Study of Patients Being Treated With ORGOVYX | Not listed | Completed | Oct 4, 2022 | Jun 30, 2026 (actual) |
| NCT05605964 | Randomized Study to Evaluate MACE in Patients With Prostate Cancer Treated With Relugolix or Leuprolide Acetate | Phase 3 | Completed | Jan 28, 2023 | Dec 31, 2024 (actual) |
| NCT06891885 | A Study to Investigate the Safety of DSP-3077 After a Unilateral Eye Injection in Male and Female Participants 18 Years of Age or Older With Retinitis Pigmentosa | Phase 1/Phase 2 | Recruiting | Apr 16, 2026 | Oct 31, 2028 (estimated) |
| NCT07492355 | TP-3654 Food Effect Study | Phase 1 | Completed | Mar 4, 2024 | May 31, 2024 (actual) |
| NCT04988555 | A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1) | 1 | Recruiting | Feb 28, 2022 | Jun 30, 2027 (estimated) |
| NCT06753331 | A Multicenter Study to Evaluate Safety, Tolerability, and Clinical Responses of DSP-1083 Into Subjects With Parkinson's Disease | Phase 1/Phase 2 | Recruiting | Dec 18, 2024 | Dec 15, 2030 (estimated) |
| NCT06517940 | A Prospective, Observational Study in Adults With Retinitis Pigmentosa (RP) | Not listed | Active, not recruiting | Oct 3, 2024 | Apr 24, 2026 (estimated) |
| NCT04666129 | Study of Relugolix in Men With Metastatic Castration-Sensitive Prostate Cancer or Non-Metastatic or Metastatic Castration-Resistant Prostate Cancer | Phase 1 | Completed | Feb 18, 2021 | May 28, 2024 (actual) |
| NCT04328740 | Phase 1 Study of Oral TP-1454 | 1 | Completed | Jul 8, 2020 | Apr 25, 2025 (actual) |
| NCT06037668 | A Randomized, Controlled Study of Two At-Home Self-Guided Virtual Reality Interventions for Adults With Social Anxiety Disorder. | Not phased (device or behavioral study) | Completed | Sep 8, 2023 | Dec 22, 2023 (actual) |
| NCT05227209 | A Clinical Trial to Determine the Long-term Safety and Tolerability of an Investigational Drug in People With Major Depressive Episode Associated With Bipolar I Disorder (Bipolar I Depression). | Phase 3 | Terminated | Mar 17, 2022 | Nov 17, 2023 (actual) |
| NCT05169710 | A Clinical Study of an Investigational Drug for the Treatment of Major Depressive Episode Associated With Bipolar I Disorder. | Phase 3 | Terminated | Dec 21, 2021 | Oct 18, 2023 (actual) |
| NCT06389955 | Assessment of Relative Bioavailability and Effect of Food on Capsule and Tablet Formulations of TP-3654 | Phase 1 | Completed | May 22, 2023 | Aug 1, 2023 (actual) |
| NCT03604783 | Phase 1, First-in-human Study of Oral TP-1287 in Patients with Advanced Solid Tumors | 1 | Terminated | Dec 26, 2018 | Jan 10, 2024 (actual) |
| NCT03416335 | A Study of DSP-0509 in Patients With Advanced Solid Tumors to Determine the Safety and the Pharmacokinetic Profile | Phase 1/Phase 2 | Terminated | Jun 1, 2018 | Dec 20, 2022 (actual) |
| NCT03311334 | A Study of DSP-7888 Dosing Emulsion in Combination With Immune Checkpoint Inhibitors in Adult Patients With Advanced Solid Tumors | Phase 1/Phase 2 | Terminated | Dec 14, 2017 | Oct 19, 2022 (actual) |
| NCT02542696 | Open-Label Phase 3 Study to Examine the Long-Term Safety, Tolerability and Efficacy of APL-130277 for the Acute Treatment of "OFF" Episodes in Patients With Parkinson's Disease | 3 | Completed | Aug 31, 2015 | Nov 8, 2022 (actual) |
| NCT02231723 | A Study of BBI608 in Combination With Standard Chemotherapies in Adult Patients With Pancreatic Cancer | Phase 1 | Completed | 2014-08 | 2020-06 (actual) |
| NCT02315534 | A Study of BBI608 in Combination With Temozolomide in Adult Patients With Recurrent or Progressed Glioblastoma | Phase 1/Phase 2 | Completed | 2015-03 | Oct 9, 2018 (actual) |
| NCT02993731 | A Study of Napabucasin Plus Nab-Paclitaxel With Gemcitabine in Adult Patients With Metastatic Pancreatic Adenocarcinoma | Phase 3 | Completed | 2016-12 | 2020-03 (actual) |
| NCT02279719 | A Study of BBI608 in Combination With Sorafenib, or BBI503 in Combination With Sorafenib in Adult Patients With Hepatocellular Carcinoma | Phase 1/Phase 2 | Completed | 2014-12 | 2019-07 (actual) |
| NCT02753127 | A Study of Napabucasin (BBI-608) in Combination With FOLFIRI in Adult Patients With Previously Treated Metastatic Colorectal Cancer | Phase 3 | Completed | 2016-06 | Apr 28, 2020 (actual) |
| NCT02024607 | A Study of BBI608 in Combination With Standard Chemotherapies in Adult Patients With Advanced Gastrointestinal Cancer | Phase 1/Phase 2 | Completed | 2014-01 | 2019-03 (actual) |
| NCT01325441 | A Study of BBI608 Administered With Paclitaxel in Adult Patients With Advanced Malignancies | Phase 1/Phase 2 | Completed | 2011-04 | Jun 1, 2021 (actual) |
| NCT03298984 | Ph I Study of Alvocidib and Cytarabine/Daunorubicin (7+3) in Patients With Newly Diagnosed Acute Myeloid Leukemia (AML). | Phase 1 | Completed | Sep 25, 2017 | Mar 20, 2020 (actual) |
| NCT02432690 | A Study of BBI503 in Asymptomatic Recurrent Ovarian Cancer Patients With CA-125 Elevation | Phase 2 | Terminated | 2015-06 | Jan 2, 2017 (actual) |
| NCT02178956 | A Study of BBI608 Plus Weekly Paclitaxel to Treat Gastric and Gastro-Esophageal Junction Cancer | Phase 3 | Completed | 2014-10 | Sep 20, 2017 (actual) |
| NCT02826161 | A Study of Napabucasin (BBI-608) Plus Weekly Paclitaxel Versus Weekly Paclitaxel Alone in Patients With Advanced, Previously Treated, Non-Squamous Non-Small Cell Lung Cancer | Phase 3 | Terminated | 2016-11 | Apr 24, 2017 (actual) |
| NCT03149003 | A Study of DSP-7888 Dosing Emulsion in Combination With Bevacizumab in Patients With Recurrent or Progressive Glioblastoma Following Initial Therapy | Phase 3 | Completed | Dec 8, 2017 | Aug 30, 2021 (actual) |
| NCT02520011 | Alvocidib Biomarker-driven Phase 2 AML Study | 2 | Terminated | Mar 14, 2016 | Feb 12, 2020 (actual) |
| NCT01776307 | A Study of BBI608 in Adult Patients With Advanced Colorectal Cancer | Phase 2 | Completed | 2012-03 | 2018-06 (actual) |
| NCT01781455 | A Study of BBI503 in Adult Patients With Advanced Solid Tumors | Phase 1 | Completed | 2012-02 | 2020-06 (actual) |
| NCT02467361 | A Study of BBI608 Administered in Combination With Immune Checkpoint Inhibitors in Adult Patients With Advanced Cancers | Phase 1 | Completed | 2015-08 | Jan 29, 2021 (actual) |
| NCT03429218 | First-in-human Study of Oral TP-0184 in Patients With Advanced Solid Tumors | Phase 1 | Completed | Jul 10, 2018 | Mar 8, 2021 (actual) |
| NCT02352558 | A Study of BBI608 in Adult Patients With Advanced, Refractory Hematologic Malignancies | Phase 1 | Completed | 2015-05 | Dec 14, 2018 (actual) |
| NCT03416816 | A Study of DSP-0337 in Patients With Advanced Solid Tumors to Determine the Safety and the Pharmacokinetic Profile | Phase 1 | Terminated | May 15, 2018 | Jun 15, 2020 (actual) |
| NCT02483247 | A Study of BBI503 in Combination With Selected Anti-Cancer Therapeutics in Adult Patients With Advanced Cancer | Phase 1 | Completed | 2015-09 | 2019-05 (actual) |
| NCT02232646 | A Study of BBI503 in Adult Patients With Advanced Urologic Malignancies | Phase 2 | Withdrawn | 2017-01 | Aug 1, 2018 (actual) |
| NCT02232620 | A Study of BBI503 in Adult Patients With Advanced Gastrointestinal Stromal Tumors | Phase 2 | Terminated | Mar 13, 2017 | Jul 25, 2017 (actual) |
| NCT02498665 | A Study of DSP-7888 Dosing Emulsion in Adult Patients With Advanced Malignancies | Phase 1 | Completed | 2015-11 | 2018-08 (actual) |
| NCT02232633 | A Study of BBI503 in Adult Patients With Advanced Hepatobiliary Cancer | Phase 2 | Completed | 2015-02 | Dec 14, 2017 (actual) |
| NCT03411122 | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Drug Interaction Potential of Napabucasin in Healthy Volunteers | Phase 1 | Completed | Jun 30, 2017 | Jan 23, 2018 (actual) |
| NCT01775423 | A Study of BBI608 in Adult Patients With Advanced Malignancies | Phase 1 | Completed | 2009-03 | Aug 6, 2015 (actual) |
| NCT03715504 | Study of TP-3654 in Patients With Advanced Solid Tumors | Phase 1 | Completed | Apr 16, 2019 | Mar 30, 2021 (actual) |
| NCT02729298 | First-in-human Study of Oral TP-0903 (a Novel Inhibitor of AXL Kinase) in Patients With Advanced Solid Tumors | Phase 1 | Completed | Dec 14, 2016 | Jun 29, 2022 (actual) |
| NCT03969420 | Study of Alvocidib in Patients With Relapsed/Refractory AML Following Treatment With Venetoclax Combination Therapy | Phase 2 | Terminated | Jan 15, 2020 | Apr 22, 2021 (actual) |
FDA records (last 2 years)
- FDA New indication / efficacy supplement: ORGOVYX (relugolix) — NDA214621/6, Oct 18, 2024. Applicant at approval: Sumitomo Pharma America, Inc. source ↗
Connect
See your connections at Sumitomo Pharma America on LinkedIn (search by name, results not checked)